Oncopeptides AB (publ) (STO:ONCO)

Market Cap	463.60M +43.6%
Revenue (ttm)	71.12M +124.7%
Net Income	-249.59M
EPS	-1.10
Shares Out	272.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,672,354
Average Volume	2,180,364
Open	1.680
Previous Close	1.700
Day's Range	1.606 - 1.698
52-Week Range	1.100 - 6.960
Beta	-1.70
RSI	22.42
Earnings Date	Feb 19, 2026

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hyd...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 75
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ONCO

Financial Performance

In 2025, Oncopeptides AB's revenue was 71.12 million, an increase of 124.72% compared to the previous year's 31.65 million. Losses were -249.59 million, -12.31% less than in 2024.